Litt's app available free to subscribers - download for IOS and Android from the App Store or Google Play.
- TRADE NAME: Talzenna (Pfizer)
- INDICATIONS: indicated for the treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm) HER2-negative locally advanced or metastatic breast cancer.
- CLASS: Poly (ADP-ribose) polymerase (PARP) inhibitor
- HALF-LIFE: 90 hours
- FDA APPROVAL DATE: 10/16/2018
- CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
Amiodarone, Carvedilol, Clarithromycin, Itraconazole, Verapamil - PREGNANCY: can cause embryo-fetal harm
- See adverse reactions attributed to class:
Please login to view the rest of this drug profile.
Page last updated 08/13/2024
